<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Deregulated c-Myc expression is a hallmark of several human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> where it promotes proliferation and an aggressive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> phenotype </plain></SENT>
<SENT sid="1" pm="."><plain>Myc overexpression is associated with reduced activity of Rel/NF-kappaB, transcription factors that control the immune response, cell survival, and transformation, and that are frequently altered in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The Rel/NF-kappaB family member NFKB2 is altered by chromosomal translocations or deletions in lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> and deletion of the C-terminal ankyrin domain of NF-kappaB2 augments lymphocyte proliferation </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Precancerous Emicro-Myc-transgenic B cells, Emicro-Myc <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and human Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> samples were assessed for Nfkb2 expression </plain></SENT>
<SENT sid="4" pm="."><plain>The contribution of Nfkb2 to Myc-driven <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, proliferation, and <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> was tested genetically in vivo </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Here we report that the Myc oncoprotein suppresses Nfkb2 expression in vitro in primary mouse fibroblasts and B cells, and in vivo in the Emicro-Myc transgenic mouse model of human Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) </plain></SENT>
<SENT sid="6" pm="."><plain>NFKB2 suppression by Myc was also confirmed in primary human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Promoter-reporter assays indicate that Myc-mediated suppression of Nfkb2 occurs at the level of transcription </plain></SENT>
<SENT sid="8" pm="."><plain>The contribution of Nfkb2 to Myc-driven <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> was tested in vivo, where Nfkb2 loss was shown to accelerate <z:hpo ids='HP_0002665'>lymphoma</z:hpo> development in Emicro-Myc transgenic mice, by impairing Myc's apoptotic response </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Nfkb2 is suppressed by c-Myc and harnesses Myc-driven <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>These data thus link Myc-driven <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> to the non-canonical NF-kappaB pathway </plain></SENT>
</text></document>